These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26380887)

  • 1. New guideline on treatment of idiopathic pulmonary fibrosis.
    Spagnolo P; Bonella F; Maher TM
    Lancet Respir Med; 2015 Sep; 3(9):e31-e32. PubMed ID: 26380887
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel treatments for idiopathic pulmonary fibrosis.
    Spagnolo P
    Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299
    [No Abstract]   [Full Text] [Related]  

  • 3. Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
    Ryerson CJ; Collard HR
    Thorax; 2014 Sep; 69(9):791-2. PubMed ID: 24996636
    [No Abstract]   [Full Text] [Related]  

  • 4. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic advances in idiopathic pulmonary fibrosis.
    George G; Vaid U; Summer R
    Clin Pharmacol Ther; 2016 Jan; 99(1):30-2. PubMed ID: 26502087
    [No Abstract]   [Full Text] [Related]  

  • 6. Two therapies now available for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2014 Dec; 23(12):47-8. PubMed ID: 25939185
    [No Abstract]   [Full Text] [Related]  

  • 7. [The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].
    Kashiwada T; Azuma A
    Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):970-6. PubMed ID: 30168687
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trial research in focus: why do so many clinical trials fail in IPF?
    Spagnolo P; Maher TM
    Lancet Respir Med; 2017 May; 5(5):372-374. PubMed ID: 28412184
    [No Abstract]   [Full Text] [Related]  

  • 9. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 10. Update in Interstitial Lung Disease 2014.
    Belloli EA; Martinez FJ; Flaherty KR
    Am J Respir Crit Care Med; 2015 Sep; 192(5):538-43. PubMed ID: 26561676
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
    Kingwell K
    Nat Rev Drug Discov; 2014 Jul; 13(7):483-4. PubMed ID: 24981347
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluating new treatment options.
    Nathan SD
    Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new era of drug therapy for idiopathic pulmonary fibrosis.
    Crooks MG; Hart SP
    Lancet Respir Med; 2014 Dec; 2(12):964-6. PubMed ID: 25466348
    [No Abstract]   [Full Text] [Related]  

  • 15. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatments in idiopathic pulmonary fibrosis.
    Strâmbu I
    Pneumologia; 2016; 65(3):127-32. PubMed ID: 29542881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antifibrotic treatment].
    von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462
    [No Abstract]   [Full Text] [Related]  

  • 19. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
    King CS; Nathan SD
    Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
    [No Abstract]   [Full Text] [Related]  

  • 20. Recommendations for perioperative management of new pharmacological antifibrotic therapy in idiopathic pulmonary fibrosis.
    González Larrocha O; Romero Rojano P; Ortega Mera U; Arízaga Maguregui A
    Rev Esp Anestesiol Reanim (Engl Ed); 2018 Mar; 65(3):178-179. PubMed ID: 29183632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.